Effectiveness of switching from first-generation basal insulin to Glargine 300 U/mL in children and adolescents with type 1 diabetes: results from the ISPED CARD database.
Glargine 300 U/mL
Pediatric diabetes
Real-world evidence
Type 1 diabetes
Journal
Acta diabetologica
ISSN: 1432-5233
Titre abrégé: Acta Diabetol
Pays: Germany
ID NLM: 9200299
Informations de publication
Date de publication:
24 May 2024
24 May 2024
Historique:
received:
21
02
2024
accepted:
10
05
2024
medline:
25
5
2024
pubmed:
25
5
2024
entrez:
24
5
2024
Statut:
aheadofprint
Résumé
Glargine 300 U/mL (Gla-300) has been recently approved for use in children and adolescents with type 1 diabetes (T1D). However, real-world effectiveness data are scarce, and aim of this analysis was to assess clinical outcomes in young patients with T1D switching from 1st generation basal insulin (1BI) to Gla-300. ISPED CARD is a retrospective, multicenter study, based on data anonymously extracted from Electronic Medical Records. The study involved a network of 20 pediatric diabetes centers. Data on all patients aged < 18 years with T1D switching from 1BI to Gla-300 were analyzed to assess clinical characteristics at the switch and changes after 6 and 12 months in glycated hemoglobin (HbA1c), fasting blood glucose (FBG), and standardized body mass index (BMI/SDS). Titration of basal and short-acting insulin doses was also evaluated. Overall, 200 patients were identified. The mean age at the switch to Gla-300 was 13 years, and mean duration of diabetes was 3.9 years. Average HbA1c levels at switch were 8.8%. After 6 months, HbA1c levels decreased by - 0.88% (95% CI - 1.28; - 0.48; p < 0.0001). The benefit was maintained after 12 months from the switch (mean reduction of HbA1c levels - 0.80%, 95% CI - 1.25; - 0.35, p = 0.0006). Trends of reduction in FBG levels were also evidenced both at 6 months and 12 months. No significant changes in short-acting and basal insulin doses were documented. The study provides the first real-world evidence of the effectiveness of Gla-300 in children and adolescents with T1D previously treated with 1BI. The benefits in terms of HbA1c levels reduction were substantial, and sustained after 12 months. Additional benefits can be expected by improving the titration of insulin doses.
Identifiants
pubmed: 38789610
doi: 10.1007/s00592-024-02304-2
pii: 10.1007/s00592-024-02304-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
G P Bracciolini
(GP)
V Cherubini
(V)
A Bobbio
(A)
S Zucchini
(S)
T Suprani
(T)
V De Donno
(V)
F Lombardo
(F)
R Bonfanti
(R)
A Franzese
(A)
I Rabbone
(I)
V Graziani
(V)
M Zampolli
(M)
I Rutigliano
(I)
L de Sanctis
(L)
L P Guerraggio
(LP)
R Franceschi
(R)
G Tornese
(G)
F Franco
(F)
C Maffeis
(C)
C Arnaldi
(C)
Informations de copyright
© 2024. Springer-Verlag Italia S.r.l., part of Springer Nature.
Références
de Bock M, Codner E, Craig ME et al (2022) ISPAD Clinical Practice Consensus Guidelines 2022: glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes. Pediatr Diabetes 23:1270–1276. https://doi.org/10.1111/pedi.13455
doi: 10.1111/pedi.13455
pubmed: 36537523
pmcid: 10107615
Cengiz E, Danne T, Ahmad T et al (2022) ISPAD clinical practice consensus guidelines 2022: insulin treatment in children and adolescents with diabetes. Pediatr Diabetes 23:1277–1296. https://doi.org/10.1111/pedi.13442
doi: 10.1111/pedi.13442
pubmed: 36537533
Limbert C, Tinti D, Malik F et al (2022) ISPAD clinical practice consensus guidelines 2022: the delivery of ambulatory diabetes care to children and adolescents with diabetes. Pediatr Diabetes 23:1243–1269. https://doi.org/10.1111/pedi.13417
doi: 10.1111/pedi.13417
pubmed: 36537530
Anderson BJ, Laffel LM, Domenger C et al (2017) Factors associated with diabetes-specific health-related quality of life in youth with type 1 diabetes: the global TEENs study. Diabetes Care 40:1002–1009
doi: 10.2337/dc16-1990
pubmed: 28546221
pmcid: 5864137
Driscoll KA, Raymond J, Naranjo D, Patton SR (2016) Fear of hypoglycemia in children and adolescents and their parents with type 1 diabetes. Curr Diab Rep 16:77
doi: 10.1007/s11892-016-0762-2
pubmed: 27370530
pmcid: 5371512
Foster NC, Beck RW, Miller KM et al (2019) State of type 1 diabetes management and outcomes from the T1D exchange in 2016–2018. Diabetes Technol Ther 21:66–72. https://doi.org/10.1089/dia.2018.0384
doi: 10.1089/dia.2018.0384
pubmed: 30657336
pmcid: 7061293
Witsch M, Kosteria I, Kordonouri O et al (2016) Possibilities and challenges of a large international benchmarking in pediatric diabetology-The SWEET experience. Pediatr Diabetes 17(Suppl 23):7–15. https://doi.org/10.1111/pedi.12432
doi: 10.1111/pedi.12432
pubmed: 27982492
Van Loocke M, Battelino T, Tittel SR et al (2021) Lower HbA1c targets are associated with better metabolic control. Eur J Pediatr 180:1513–1520. https://doi.org/10.1007/s00431-020-03891-2
doi: 10.1007/s00431-020-03891-2
pubmed: 33415466
Bailey TS, Pettus J, Roussel R et al (2018) Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes. Diabetes Metab 44:15–21
doi: 10.1016/j.diabet.2017.10.001
pubmed: 29153485
Heise T, Hovelmann U, Nosek L, Hermanski L, Bottcher SG, Haahr H (2015) Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Expert Opin Drug Metab Toxicol 11:1193–1201
doi: 10.1517/17425255.2015.1058779
pubmed: 26086190
Tumini S, Carinci S (2017) Unmet needs in children with diabetes: the role of basal insulin. Minerva Pediatr 69:513–530. https://doi.org/10.23736/S0026-4946.17.05112-X
doi: 10.23736/S0026-4946.17.05112-X
pubmed: 29181962
Roussel R, Ritzel R, Boëlle-Le Corfec E, Balkau B, Rosenstock J (2018) Clinical perspectives from the BEGIN and EDITION programmes Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM. Diabetes Metab 44:402–409
doi: 10.1016/j.diabet.2018.02.002
pubmed: 29548798
Danne T, Tamborlane WV, Malievsky OA et al (2020) Efficacy and safety of insulin glargine 300 Units/mL (Gla-300) versus insulin glargine 100 Units/mL (Gla-100) in children and adolescents (6–17 years) with type 1 diabetes: results of the EDITION JUNIOR randomized controlled trial. Diabetes Care 43:1512–1519
doi: 10.2337/dc19-1926
pubmed: 32430458
pmcid: 7305011
Urakami T, Mine Y, Aoki M, Okuno M, Suzuki J (2017) A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes. Endocr J 64:133–140
doi: 10.1507/endocrj.EJ16-0294
pubmed: 27746408
Maffeis C, Rabbone I (2022) Insulin glargine 300 U/mL therapy in children and adolescents with type 1 diabetes. Paediatr Drugs 24:499–512
doi: 10.1007/s40272-022-00520-3
pubmed: 35881330
pmcid: 9439977
Berger ML, Sox H, Willke RJ et al (2017) Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE special task force on real-world evidence in health care decision making. Value Health 20:1003–1008. https://doi.org/10.1016/j.jval.2017.08.3019
doi: 10.1016/j.jval.2017.08.3019
pubmed: 28964430
Thalange N, Deeb L, Iotova V et al (2015) Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes. Pediatr Diabetes 16:164–176. https://doi.org/10.1111/pedi.12263
doi: 10.1111/pedi.12263
pubmed: 25683037
pmcid: 4413367
Predieri B, Suprani T, Maltoni G et al (2018) Switching from glargine to degludec: the effect on metabolic control and safety during 1-year of real clinical practice in children and adolescents with type 1 diabetes. Front Endocrinol (Lausanne) 9:462. https://doi.org/10.3389/fendo.2018.00462
doi: 10.3389/fendo.2018.00462
pubmed: 30190702
Kochar IS, Sethi A (2018) Real-world efficacy and safety of insulin degludec with mealtime rapid-acting insulin in type 1 diabetes in Indian pediatric population. Int J Pediatr Endocrinol 2018:6. https://doi.org/10.1186/s13633-018-0059-0
doi: 10.1186/s13633-018-0059-0
pubmed: 30069184
pmcid: 6064114
Urakami T, Kuwabara R, Aoki M, Okuno M, Suzuki J (2016) Efficacy and safety of switching from insulin glargine to insulin degludec in young people with type 1 diabetes. Endocr J 63:159–167. https://doi.org/10.1507/endocrj.EJ15-0245
doi: 10.1507/endocrj.EJ15-0245
pubmed: 26632171
Schmitt J, Scott ML (2019) Insulin degludec in adolescents with Type 1 diabetes: Is newer better? - A retrospective self-control case series in adolescents with a history of diabetic ketoacidosis. Horm Res Paediatr 92:179–185. https://doi.org/10.1159/000504707
doi: 10.1159/000504707
pubmed: 31865335
Elahi S, Patel AD, Guandalini C et al (2019) Impact of switching youth with diabetes to insulin degludec in clinical practice. Endocr Pract 25:226–229. https://doi.org/10.4158/EP-2018-0417
doi: 10.4158/EP-2018-0417
pubmed: 30913005
Rabbone I, Pozzi E, Savastio S et al (2022) A comparison of the effectiveness and safety of insulin glargine 300 U/ml versus 100 U/ml in children and adolescents with newly diagnosed type 1 diabetes: a retrospective, observational, short-term study. Diabetes Obes Metab 24:2474–2477. https://doi.org/10.1111/dom.14839
doi: 10.1111/dom.14839
pubmed: 35971275
Laviola L, Porcellati F, Bruttomesso D et al (2021) Comparative effectiveness of switching from first-generation basal insulin to glargine 300 U/ml or degludec 100 U/ml in Type 1 diabetes: the RESTORE-1 study. Diabetes Ther 12:509–525. https://doi.org/10.1007/s13300-020-00982-z
doi: 10.1007/s13300-020-00982-z
pubmed: 33351177
Conget I, Mangas MÁ, Morales C et al (2021) Effectiveness and safety of insulin glargine 300 U/ml in comparison with insulin degludec 100 U/ml evaluated with continuous glucose monitoring in adults with type 1 diabetes and suboptimal glycemic control in routine clinical practice: the OneCARE study. Diabetes Ther 12:2993–3009. https://doi.org/10.1007/s13300-021-01153-4
doi: 10.1007/s13300-021-01153-4
pubmed: 34599749
pmcid: 8519995
Nicolucci A, Graziano G, Lombardo F et al (2024) ISPED CARD Study Group Continuous improvement of quality of care in pediatric diabetes: the ISPED CARD clinical registry. Acta Diabetol 61:599–607. https://doi.org/10.1007/s00592-023-02233-6
doi: 10.1007/s00592-023-02233-6
pubmed: 38332378
pmcid: 11055792
Rossi MC, Nicolucci A, Arcangeli A et al (2008) Baseline quality-of-care data from a quality-improvement program implemented by a network of diabetes outpatient clinics. Diabetes Care 31:2166–2168. https://doi.org/10.2337/dc08-0469
doi: 10.2337/dc08-0469
pubmed: 18694979
pmcid: 2571068
Rossi MC, Candido R, Ceriello A et al (2015) Trends over 8 years in quality of diabetes care: results of the AMD Annals continuous quality improvement initiative. Acta Diabetol 52:557–571. https://doi.org/10.1007/s00592-014-0688-6
doi: 10.1007/s00592-014-0688-6
pubmed: 25528003
Stahl-Pehe A, Kamrath C, Prinz N et al (2022) Prevalence of type 1 and type 2 diabetes in children and adolescents in Germany from 2002 to 2020: A study based on electronic health record data from the DPV registry. J Diabetes 14:840–850. https://doi.org/10.1111/1753-0407.13339
doi: 10.1111/1753-0407.13339
pubmed: 36515004
pmcid: 9789390
Beck RW, Tamborlane WV, Bergenstal RM et al (2012) The T1D exchange clinic registry. J Clin Endocrinol Metab 97:4383–4389. https://doi.org/10.1210/jc.2012-1561
doi: 10.1210/jc.2012-1561
pubmed: 22996145
Joshi SR, Singh G, Marwah A, Mittra S, Suvarna VR, Athalye SN (2023) Comparative clinical efficacy and safety of insulin glargine 300 U/ml (Toujeo) versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: a systematic literature review and meta-analysis. Diabetes Obes Metab 25:1589–1606. https://doi.org/10.1111/dom.15007
doi: 10.1111/dom.15007
pubmed: 36748186
Bratke H, Margeirsdottir HD, Assmus J, Njølstad PR, Skrivarhaug T (2021) Does current diabetes technology improve metabolic control? A cross-sectional study on the use of insulin pumps and continuous glucose monitoring devices in a nationwide pediatric population. Diabetes Ther 12:2571–2583. https://doi.org/10.1007/s13300-021-01127-6
doi: 10.1007/s13300-021-01127-6
pubmed: 34389930
pmcid: 8385028
Laffel LM, Kanapka LG, Beck RW et al (2020) Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: a randomized clinical trial. JAMA 323:2388–2396. https://doi.org/10.1001/jama.2020.6940
doi: 10.1001/jama.2020.6940
pubmed: 32543683
pmcid: 7298603